Report: Midcap biotechs boost R&D investment in Q3 2012

03/8/2013 | American City Business Journals

Midcap biotech companies spent $746.8 million on research and development in the third quarter of 2012, an increase from $621.1 million in the same period of 2011, according to a report from GlobalData. The focus of research programs is cancer treatment, "which is driving peer group R&D expenses higher," an analyst said.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Claims Director
PacificSource
Springfield, OR
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Food Lawyer
Cargill
Wayzata, MN
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY